Blue Cross Blue Shield - Iowa PSFS Coverage Update

Coverage Determination and Evidence Summary

inv-01: Not covered — investigational

Coverage determination

Investigational Coverage Determination: Peripheral subcutaneous field stimulation is considered investigational for all indications because the evidence is insufficient to determine the effects of the technology on net health outcomes.

Based on randomized trials, nonrandomized comparative studies, and case series with methodological limitations, short follow-up, and device-related adverse events; larger controlled trials comparing PFS/PNFS with placebo or alternative treatments are needed.

inv-02: Evidence summary / contexts with observed benefit

Evidence summary and situations where benefit was observed

Randomized evidence: Randomized trials include a crossover RCT (McRoberts et al., n=44) that compared stimulation parameters and found within-group improvements (24/30 completers had ≥50% reduction in pain), and a multicenter open-label RCT (n=116) reporting a significantly higher response rate at 9 months for peripheral subcutaneous field stimulation plus medical management versus medical management alone.

Both trials had important limitations including lack of blinding (crossover RCT lacked sham/comparator), high loss to follow-up, and early termination for recruitment difficulties; device-related adverse events were reported.

Case series evidence: Multiple case series, including prospective multicenter series with >100 patients (Kloimstein et al.; Verrills et al.), report clinically meaningful reductions in pain scores and decreases in analgesic use after implantation; many series required a successful percutaneous trial (commonly ≥7 days) with ≥50% pain reduction prior to permanent implant.

Adverse events reported across series include lead dislocation/fracture, infection, lead/battery migration, and unpleasant sensations.

Guideline and health-technology guidance: Professional guidance notes potential role of peripheral nerve stimulation for select indications, but external reviews (NICE 2013) concluded current evidence for PNFS/PFS is limited in quantity and quality and that safety data and duration of follow-up are limited.

ASPN/other society guidance may discuss implantable peripheral nerve stimulation broadly, but some guidelines do not specifically endorse routine use of subcutaneous field stimulation given evidence limitations.

Peripheral subcutaneous field stimulation (PSFS) is described in regulatory context as an off-label use of FDA‑approved peripheral nerve stimulation systems that are indicated for chronic pain by targeting peripheral nerves. The policy notes this regulatory status when considering coverage and exclusions.

The National Institute for Health and Care Excellence (NICE) concluded that the available evidence for peripheral nerve‑field stimulation is limited in both quantity and quality, with a limited duration of follow‑up, and that safety data are also limited; NICE did not recommend routine use given these evidence limitations.

Within the cited document excerpts there are no explicit clinical exclusions listed for peripheral subcutaneous field stimulation; coding guidance and general reporting instructions are provided, but specific patient exclusion criteria are not specified in these chunks.

This policy states that peripheral subcutaneous field stimulation is considered investigational for all indications and, as such, is regarded as not medically necessary under the terms of this policy.

NICE’s assessment emphasizes that when high‑quality evidence is lacking or long‑term benefit has not been demonstrated, the therapy may be considered investigational; this conclusion supports treating peripheral subcutaneous field stimulation as investigational in the absence of stronger evidence.

In the provided excerpts there are no explicit statements labeled as 'not medically necessary' beyond the investigational coverage stance; coding and reporting instructions appear but do not state additional formal 'not medically necessary' language in these chunks.

Coding and Procedure Reporting

Coding referencedmixed

No codes listed

CPT - UnlistedCPT

64999

Unlisted procedure, nervous system

HCPCS / Othermixed

None

inv-12: Trial pain reduction threshold

Threshold>= 50% pain reduction during percutaneous trial

ContextTrial commonly performed prior to permanent implantation (permanent implantation preceded by trial)

Trial duration noted in case seriesAt least 7 days in some series before permanent implant

inv-13: Trial stimulation success threshold

Success threshold≥50% pain reduction during trial (commonly used to define successful trial)

Evidence sourceCase series and prospective studies required ≥50% reduction for permanent implantation

Provider Requirements, Billing and Documentation

Prior Authorization

Prior Authorization and Coding

Prior authorization is required for implantation procedures. Report services using appropriate CPT/HCPCS; when no specific CPT exists for the procedure, report using unlisted procedure code 64999 (Unlisted procedure, nervous system). Failure to obtain prior authorization or to use appropriate coding may result in claim denial.

Prior authorization required for implantation and associated procedures
If no specific CPT exists, report with 64999 (Unlisted procedure, nervous system)
Use appropriate HCPCS, Revenue and ICD-10 diagnosis codes as applicable

Denial Risk

Investigational — Denial Risk

Peripheral subcutaneous field stimulation is considered investigational for all indications. Procedures or services for investigational indications are subject to denial. Providers should verify coverage prior to proceeding and ensure documentation supports medical necessity; absence of supportive documentation may lead to claim denial.

Conservative Therapy Expectations and Selection Criteria

Key Terms and Definitions

inv-28: Peripheral subcutaneous field stimulation (PSFS)

DefinitionPeripheral subcutaneous field stimulation (PSFS) is a modification of peripheral nerve stimulation in which leads are placed subcutaneously within the area of maximal pain to stimulate cutaneous afferents or dermatomal distributions.

ObjectiveStimulate region of affected nerves or dermatomes to modulate pain signals converging on the spinal cord

Indications notedInvestigational for multiple focal neuropathic pain syndromes; no consensus on indications

inv-29: Trial stimulation

DefinitionTrial stimulation: a percutaneous stimulation trial prior to permanent implantation, commonly expecting at least 50% pain reduction.

Common practice

Procedure Frequency and Implantation Notes

inv-36: Permanent implantation after trial

Practice after successful trialPermanent implantation typically follows a successful percutaneous trial demonstrating at least 50% pain reduction

Trial-to-implant timingSome series required a trial period of ≥7 days prior to permanent implant

DocumentationPermanent implantation numbers reported (eg, 105 of 118 in a prospective multicenter study) after trial success

inv-37: Peripheral nerve field stimulation

Procedure termPeripheral nerve field stimulation (PNFS) refers to implantable stimulation of subcutaneous tissues or peripheral nerves for focal chronic pain.

Reported outcomesCase series report pain reductions (eg, 69% with ≥50% improvement in one series) and decreased analgesic use in many patients

Imaging and Pre-procedure Evaluations

Note

PSFS — none specified

No patient selection/follow-up scales (PSFS) are specified in these policy excerpts.

Note

Imaging requirements — none specified

No specific imaging requirements are stated in the cited policy text.

Note

No imaging requirements specified

The policy text and referenced chunks do not list any imaging requirements for PSFS in this portion of the document.

Background and Rationale

Peripheral subcutaneous field stimulation (PSFS) is a neuromodulation modification of peripheral nerve stimulation in which leads are placed subcutaneously within the area of maximal pain to stimulate cutaneous afferents or dermatomal distributions with the goal of modulating pain signals.

Not Covered / Exclusions

Peripheral subcutaneous field stimulation is designated in this policy as investigational for all indications and therefore is listed as not covered. Providers should use appropriate reporting codes (for example, unlisted CPT 64999 when no specific CPT exists) when submitting claims, but requests remain subject to denial because of the investigational stance.

As reflected in the policy, peripheral subcutaneous field stimulation is considered investigational for all indications and is therefore treated as not covered; coding guidance in the document references the unlisted procedure code 64999 for nervous system procedures when a specific CPT is not available.

The provided excerpts do not enumerate specific procedures or indications beyond the general investigational/not covered designation; no additional explicit 'not covered' procedures or indications are listed in these chunks.

OpenPayer

Peripheral Subcutaneous Field Stimulation (PSFS) Coverage Policy

Coverage Determination and Evidence Summary

Coding and Procedure Reporting

Provider Requirements, Billing and Documentation

Conservative Therapy Expectations and Selection Criteria

Key Terms and Definitions

Procedure Frequency and Implantation Notes

Imaging and Pre-procedure Evaluations

Background and Rationale

Not Covered / Exclusions